Statement by Sung Poblete, CEO of FARE, regarding FDA’s May 20, 2022 approval of Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE)

“FARE (Food Allergy Research and Education) supports and applauds the FDA’s first-ever approval of a biologic therapy for the chronic immune disorder of Eosinophilic Esophagitis (EoE). The approval of Dupixent (dupilumab) for use in adults and pediatric patients 12 years and older is a milestone in addressing treatments for many in the food allergy community.

“FARE is heartened by the FDA’s commitment to the more than 32 million Americans living with life threatening food allergies. While there is no singular approach that helps everyone with EoE, this breakthrough approval offers another, much-needed treatment option for these patients. In addition, Dupixent is also being studied as a treatment for IgE-mediated food allergy. 

“The food allergy community and FARE are extremely thankful to all the patients and researchers who participated in the ground-breaking, two-part clinical trials to investigate the safety and efficacy of this biologic therapy for EoE. FARE is also grateful for the hard work of dedicated members of the FDA advisory panel and others who led the approval efforts on this life-changing therapy.”  

Background:
A chronic immune system disease, Eosinophilic esophagitis is an allergic inflammation of the esophagus which involves a type of white blood cell that builds up in the esophageal lining. This buildup can injure the esophageal tissue, leading to extreme difficulty swallowing or causing food to get stuck when swallowing. Eosinophilic esophagitis is considered a major cause of gastrointestinal illness that usually requires urgent medical attention.
 
Link to FDA’s news release on Dupixent approval for the treatment of EoE: FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder | FDA